Chitosan-derived nanoparticles impede signal transduction in T790M lung cancer therapy

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Oncology

Background:

• Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is a major challenge in non-small cell lung cancer (NSCLC) treatment.
• The p.Thr790Met (T790M) mutation is a key driver of resistance in approximately 50% of patients.
• Developing strategies to overcome EGFR-T790M mediated resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To develop novel therapeutic nanoparticles (DGA) to overcome EGFR-T790M resistance in NSCLC.
• To investigate the synergistic effects of mitochondrial dysfunction induction and miRNA inhibition for enhanced drug delivery.
• To evaluate the in vitro and in vivo efficacy and safety of DGA nanoparticles.

Main Methods:

• Design and synthesis of chitosan-derived nanocarrier DCAFP loaded with gefitinib (GFT) and miR21 inhibitor (anti-miR21) to form DGA nanoparticles.
• Assessment of DGA nanoparticles' ability to induce mitochondrial dysfunction and inhibit miRNA expression in EGFR-T790M mutated NSCLC cells.
• Evaluation of in vitro anti-cancer efficacy, including tumor cell growth inhibition.
• In vivo studies using EGFR^T790M mutated lung cancer mouse models to assess antitumor efficacy and safety.

Main Results:

• DGA nanoparticles effectively delivered GFT and anti-miR21, inducing mitochondrial dysfunction and inhibiting miRNA expression.
• Synergistic blockade of downstream anti-apoptotic signaling pathways was observed.
• Significant inhibition of tumor cell growth in vitro was achieved.
• In vivo studies demonstrated superior antitumor efficacy and safety in mouse models of EGFR^T790M mutated lung cancer.

Conclusions:

• DGA nanoparticles represent a promising therapeutic strategy to overcome gefitinib resistance in EGFR^T790M NSCLC.
• The combination of mitochondrial dysfunction induction and miRNA inhibition offers a synergistic approach for cancer therapy.
• These findings highlight the potential of DGA nanoparticles for enhancing treatment sensitivity in resistant NSCLC.